A Single-Arm, Phase 2 Study of Ramucirumab in Combination With Weekly Docetaxel in Patients With Stage IV Non-Small Cell Lung Cancer Following Disease Progression After Prior Platinum-Based Chemotherapy
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 16 Dec 2016
At a glance
- Drugs Ramucirumab (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Eli Lilly
- 01 Dec 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 12 Oct 2016 Planned primary completion date changed from 1 Sep 2017 to 1 Jul 2017.
- 12 Oct 2016 Planned initiation date changed from 1 Oct 2016 to 1 Nov 2016.